Amy Beumer, Ph.D.
@amybeumer
Followers
600
Following
17K
Media
107
Statuses
2K
MBC advocate, microbiologist, educator, nature lover, gardener, reader, and feminist. She/her/hers.
Joined May 2014
MBC doesn’t stop just because October ends. Neither does the need for research.
As October ends and pink ribbons fade, we cannot forget Stage IV—not for a single day. Only 13% of breast cancer research funding goes to the disease that kills. Thank you for following our #METober posts. Please keep sharing and spreading the word #UntilNoOneDiesFromMBC
1
7
18
#ESMO25 🇪🇸 GEICAM “El Álamo” (n=22,989) Anthracycline-based chemotherapy significantly increased the risk of contralateral breast cancer and second primary malignancies (IRR 1.46; p=0.039). 💬 Real-world data remind us once again: long-term toxicity cannot be ignored.
Ask any breast oncologist today, and they’ll tell you they prefer anthracycline-free regimens in HER2-positive breast cancer — and that anthracyclines don’t improve response rates. So how did we accept a control arm containing anthracyclines in the DESTINY-Breast11 trial, which
2
11
25
Grateful to all our elected representatives who understand the need for research funding and supporting bills that help the MBC community. @RepJoeMorelle I’m so sorry you know the pain of having a loved one stolen by MBC far, far too soon.
Rep. Joe Morelle shares a powerful message at the Stage IV Stampede, honoring his daughter and urging support for MBC legislation. Read more on our blog here: https://t.co/yMAK9O3aCH
#StageIVStampede #MBCAdvocacy
0
2
10
I’ve been in the liver met “club” for a year or so now, thankfully responding to the treatment targeted to mutations my cancer has. I’m alive and doing pretty darn well thanks to #research. Please support @metavivor #UntilNoOneDiesFromMBC
About two-thirds of MBC patients have liver metastases at death, and 1 in 4 already have liver involvement at diagnosis. Liver transplants aren’t an option for MBC patients—another reason why we need more research for better treatments. #UntilNoOneDeisFromMBC #Research
0
4
15
Interesting study on ⬇️ bone pains by delaying timing of peg-filgrastim after taxane Though better is to omit routine peg-filgrastim, which is feasible in most pts getting dose dense paclitaxel … (we still use routine growth factor with docetaxel) https://t.co/6XQO91FCDL
pmc.ncbi.nlm.nih.gov
The use of growth factors adds considerable expense and some toxicity to adjuvant breast cancer chemotherapy. We tested the feasibility and safety of omitting routine peg-filgrastim use during the...
RCT on timing of pegfilgrastrim after CT shows significantly reduced bone pain with 72-hour timing as compared to 24- and 48-hour timing #ESMO25 @myESMO @OncoAlert
0
8
29
Let me fix this, "since ADCs have moved to standard of care it's been critical to be aware of how to mitigate their side effects". Yes, more people and different goals, but eBC v. aBC we all deserve QoL and fewer AEs. Love the focus but words matter. #bcsm #ESMO25
Grateful for the chance to chair the #ESMO25 ADC educational session & present on ADC toxicities. With ADCs moving to the curable setting across cancers, it’s critical to be aware of how to mitigate their side effects. For an in-depth dive into the topic: https://t.co/QcpeKTosCq
1
2
11
Remember that M/aBC patients have been suffering AEs for years now with little push to examine reduced dosing for efficacy + AE mitigation. Now is a good time but it shouldn't take treating eBC to put out the call. Our lives & QoL matter too. #bcsm #ESMO25
dailyreporter.esmo.org
Presidential presentations in early breast cancer provide first evidence of ADCs rapidly moving into the curative setting across multiple cancer types
2
2
8
Can HR+ MBC forego CDK 4/6 inhibitors in the first line? More data from a necessary trial showing…maybe? Dr. Graff laying out the caveats from the ongoing study #bcsm
SONIA overall survival analysis = no significant difference 1L vs 2L CDK4/6i, except premenopausal; draws same criticisms RE: low OS compared to historical trial, non-standard of care single agents & CDK4/6. Still impressive data adding value. #ESMO25 @OncoAlert
0
2
3
💯 Also…tox for TDxd & SG - how effective are reduced doses? And how do these compare in head to head? So much new data (thank you!) so much needed in this space. Don’t miss the nice comparison slide among ADCs for HR+ MBC.
🐘 The elephant in the room: we don’t know how to sequence all these TOPO1 ADCs.
0
0
0
Informative & helpful comparison slides- SG v Dato, 1st line mTNBC. Side effect profiles and dosing regimen are quite different - not a huge fan of SG’s personally but appreciate the PFS/OS. Looking forward to real world data comparing -no ADCs in either control arm. #bcsm
Wow…what a fantastic discussion at #ESMO25 by Dr. Garrido-Castro from @DFCI_BreastOnc 🙌🤩 first-line therapy in advanced triple-negative #BreastCancer not eligible for IO has finally changed !!! @OncoAlert @myESMO #bcsm
1
3
4
Great notes on day 2 - HR+ HER2- MBC and HER2+ eBC #bcsm
0
1
2
Due to the way SEER collects data, it has significantly undercounted occurrences of MBC b/c it only records instances of de novo MBC. It fails to capture metastatic recurrences, estimated to be 30% of all breast cancer patients who progress from early-stage to MBC.
1
2
5
The highest dose is not always the best dose - pembro in early TNBC. @the_rightdose #bcsm
#ESMO25 50 mg pembrolizumab every 6 weeks!! In the neoadjuvant phase of KEYNOTE-522, a similar increase in pCR was achieved with only ~10% of that dose! What is the optimal dose for immunotherapy agents?
0
2
8
Looks promising. Appears no previous ADC exposure and not in comparison arm. Need this info as we try to make informed decisions among ADCs #bcsm
More #ADC options for patients with advanced pretreated endocrine-resistance HR+/HER2- #BraestCancer: just presented at #ESMO25 positive data with use of #sacituzumabTirumotecan in this setting #OptiTROPBreast2 @OncoAlert @myESMO #bcsm
0
2
4
The good thing about some early morning insomnia? All the ESMO data :-)
0
0
2
Exactly! Very few people w/ aBC on fulvestrant monitherapy bc of more effective combos —> should NOT be using as a control.
Excellent question from the audience. Why in the world are we still using single agent fulvestrant control arms in 2025? Apparently @US_FDA mandated this in Viktoria 1.
1
1
3
#ESMO25 - Patients with metastatic breast cancer who had received ≥ 2 years of bone modifying agents🦴were randomized to continue standard dosing (Q4W) or de-escalate to Q24W De-escalation preserved physical function without increasing skeletal events @OncoAlert
1
49
123
Beautiful presentation by @elmayermd on the eVERA trial of giredestrant + everolimus vs ET+everolimus in HR+ MBC post cdk4/6i n=373 PFS in ESR1m: 9.99 vs 5.45 mo, HR 0.38 ITT: PFS 8.77 vs 5.49mo, HR 0.56 ESR1 wt: 5.72 vs 5.52mo HR 0.84 @OncoAlert @DFCI_BreastOnc @myESMO
0
0
1
“Cancer pts & their families are being pulled into the #priorauthorization process, at the expense of their time, health, & well-being” #Priorauth isn’t just an administrative hurdle for clinicians; it’s a hidden 2nd job for patients. #ascoQLTY25
https://t.co/Mw4UIH1Uxh
2
14
37
We were in DC last week, once again asking for passage of this act, which would remove the waiting periods for SSDI and Medicare. The more our representatives hear from us the more likely there will be action on this, so PLEASE contact your Congressperson and Senators!
0
4
13